Lancet Diabetes & Endocrinology
Lancet Diabetes & Endocrinology(英文缩写 LANCET DIABETES ENDO),ISSN 2213-8587,eISSN 2213-8595 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
指标来源：jcr_cas_ifqb
期刊简介
暂无简介。
历年影响因子趋势
| 年份 | 影响因子 | JCR 分区 |
|---|---|---|
| - | Q1 | |
| - | Q1 | |
| - | Q1 | |
| - | Q1 | |
| - | Q1 |
Lancet Diabetes & Endocrinology 最新收录文献
※ 中文译文由 AI 辅助生成,仅供学术参考,请以英文原文为准。
-
Once-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial.
Stepwise treatment intensification is recommended for managing type 2 diabetes, including insulin initiation when non-insulin glucose-lowering medications are insufficient. Guidelines recommend combin…
-
Effect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
The GLP-1 receptor agonist semaglutide reduces clinically important kidney outcomes in people with type 2 diabetes and chronic kidney disease (CKD). We aimed to assess the pooled effects of semaglutid…
-
Type 1 diabetes in older populations.
In recent decades, life expectancy among people with type 1 diabetes has improved substantially in many high-income countries and well resourced health-care settings, highlighting persistent global in…
-
Correction to Lancet Diabetes Endocrinol 2026; 14: 149-56.
-
Hypoparathyroidism: translating science from the laboratory to the clinic.
Chronic hypoparathyroidism is a rare endocrine disorder characterised by hypocalcaemia due to insufficient parathyroid hormone (PTH) that is associated with a multidimensional reduced quality of life,…
-
Ketoacidosis with SGLT2 inhibitors in routine clinical practice of type 2 diabetes: Scandinavian cohort and nested case-control study.
SGLT2 inhibitors increase the risk of ketoacidosis, but data from routine clinical practice are scarce. We used nationwide registers with the aim of assessing the incidence, risk factors, and prognosi…
-
Do weight loss and weight cycling present a clinically meaningful risk in older patients?
-
Soaring GLP-1 receptor agonist use.
-
Energy drink ban: putting children's health first.
-
Nutritional, functional, and psychological considerations for incretin-based therapies in adults-an EASO, EFAD, and ECPO Consensus Statement. 成人肠促胰岛素治疗的营养、功能和心理考虑——EASO、EFAD和ECPO共识声明
Incretin-based therapies, including GLP-1 receptor agonists and dual GLP-1-GIP receptor agonists, have transformed obesity management, producing substantial weight loss and cardiometabolic benefits, w…